PATENT CLAIM ANALYSIS

Application Number: 16251789
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["548", "100000"]

Abstract:
The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.

Claim (Index 24):
A compound of formula I as claimed in  claim 21 , wherein R 1  is hydrogen, methyl or ethyl.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 99.0
- Lexical Diversity: 1.51351
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15339041', '14423359', '15877103', '11719415', '11988592']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8451251986526717
- 35 USC 102 Novelty (BERT): 0.7140719951448573
- Combined Prediction Score: 0.8320198783018902
- Mean Citation Score: 641.620988
- Max Citation Score: 905.2542
- Similarity Product: 752.2758178463458

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test